Effectiveness and safety of daptomycin versus vancomycin in methicillin-resistant staphylococci left-sided infective endocarditis: results from a nationwide prospective, multicentre cohort
Clinical Microbiology and Infection · 2026
DOI: 10.1016/j.cmi.2026.04.027 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Microbiology and Infection, 2026. Verfasst von Jorge Calderón-Parra und 14 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Internal Medicine Department, Universitary Hospital Puerta de Hierro, Majadahonda, Madrid, Spain; Research Institute Hospit…. Hauptthemen laut MEDLINE: Daptomycin, Vancomycin, Anti-Bacterial Agents, Staphylococcal Infections. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: The aim of the study was to compare the effectiveness and safety of daptomycin vs. vancomycin treatment for left-sided infective endocarditis (IE) caused by methicillin-resistant staphylococci (MRS). We specifically aimed to explore the effectiveness of different daptomycin-based regimens. METHODS: This prospective, multicentre cohort study included consecutive patients with definite left-sided MRS-IE from January 2008 to December 2023. Patients were divided into two groups according to whether they received daptomycin or vancomycin as the main antibiotic. The patients in whom neither antibiotic could be considered the main antibiotic were excluded. The primary endpoint was in-hospital mortality. Multivariable logistic regression was used for adjusted in-hospital mortality and Cox regression for 1-year mortality. RESULTS: A total of 617 patients were included: 421 (68.2%) received daptomycin-based and 196 (31.8%) received vancomycin-based regimens. In the adjusted analysis, daptomycin was associated with similar in-hospital mortality as vancomycin (adjusted odds ratio [aOR]: 0.79, 95% confidence interval [CI]: 0.48-1.28). Daptomycin was associated with a significantly lower rate of adverse drug reactions (14.5% [61 of 421] vs. 26.0% [51 of 196], p 0.001), mainly driven by less acute kidney injury (8.7% [36 of 421] vs. 16.8% [32 of 196], p 0.003). In subgroup analyses, high-dose daptomycin (≥8 mg/kg) in combination was associated with lower in-hospital mortality than other daptomycin regimens (aOR: 0.55, 95% CI: 0.31-0.98) without more adverse reactions (14.5% [34 of 234] vs. 14.4% [27 of 187], p 1.000). Compared with vancomycin, the high-dose daptomycin-based combination strategy was not associated with a statistically significant difference in in-hospital mortality (aOR: 0.66, 95% CI: 0.38-1.09) but was associated with lower 1-year mortality (adjusted hazard ratio: 0.55, 95% CI: 0.31-0.98) and lower rate of adverse reactions (14.5% [34 of 234] vs. 26.0% [51 of 19], p 0.003). CONCLUSIONS: In this large, real-world cohort, daptomycin demonstrated comparable effectiveness to vancomycin. However, it was associated with lower adverse reactions. High-dose daptomycin-based combinations with a second agent could be associated with improved outcomes. This strategy could be considered as a therapeutic option for MRS-IE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Unit, Internal Medicine Department, Universitary Hospital Puerta de Hierro, Majadahonda, Madrid, Spain; Research Institute Hospital Puerta de Hierro-Segovia de Arana (IDIPHISA), Majdahonda, Madrid, S…
- Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid, Spain; CIBER of Respiratory Diseases (CIBE…
- Infectious Diseases Department, Marqués de Valdecilla University Hospital-IDIVAL, Santander, Spain; CIBER of Infectious Diseases (CIBERINFEC, CB21/13/00068), Instituto de Salud Carlos III, Madrid, Spain; Faculty of Medi…
- Infectious Diseases Department, Marqués de Valdecilla University Hospital-IDIVAL, Santander, Spain; CIBER of Infectious Diseases (CIBERINFEC, CB21/13/00068), Instituto de Salud Carlos III, Madrid, Spain.
- Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid, Spain.
- Cardiology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute, Madrid, Spain; CIBER of Cardiovascular Diseases (CIBERCV), Instituto de Salud Carlos III…
Zitieren
APA
Calderón-Parra, J., Diego-Yagüe, I., Muñoz, P., Fariñas-Alvarez, M. C., Ruiz-Alonso, N., Alvarez-Uría, A., Martínez-Sellés, M., Rodríguez-Esteban, M. A., Ojeda-Burgos, G., Goikoetxea-Agirre, A. J., De Alarcón, A., Miró, J. M., Loeches-Yagüe, B., Martínez-Ramos, A., & Spanish Collaboration on Endocarditis (GAMES) investigators (2026). Effectiveness and safety of daptomycin versus vancomycin in methicillin-resistant staphylococci left-sided infective endocarditis: results from a nationwide prospective, multicentre cohort. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2026.04.027
Vancouver
Calderón-Parra J, Diego-Yagüe I, Muñoz P, Fariñas-Alvarez MC, Ruiz-Alonso N, Alvarez-Uría A, et al. Effectiveness and safety of daptomycin versus vancomycin in methicillin-resistant staphylococci left-sided infective endocarditis: results from a nationwide prospective, multicentre cohort. Clinical Microbiology and Infection. 2026. doi:10.1016/j.cmi.2026.04.027
BibTeX
@article{CaldernParra2026,
author = {Calderón-Parra, Jorge and Diego-Yagüe, Itziar and Muñoz, Patricia and Fariñas-Alvarez, María Carmen and Ruiz-Alonso, Noelia and Alvarez-Uría, Ana and Martínez-Sellés, Manuel and Rodríguez-Esteban, Maria Angeles and Ojeda-Burgos, Guillermo and Goikoetxea-Agirre, Ane Josune and De Alarcón, Aristides and Miró, Jose Maria and Loeches-Yagüe, Belen and Martínez-Ramos, Antonio and Spanish Collaboration on Endocarditis (GAMES) investigators, Spanish Collaboration on Endocarditis (GAMES) investigators},
title = {Effectiveness and safety of daptomycin versus vancomycin in methicillin-resistant staphylococci left-sided infective endocarditis: results from a nationwide prospective, multicentre cohort},
journal = {Clinical Microbiology and Infection},
year = {2026},
doi = {10.1016/j.cmi.2026.04.027}
}
EUVIMED